CSBR Financials

Income Statement
MetricQ4 2026Q3 2026Q2 2026Q1 2026Q4 2025
Revenue
13.8M
-16.5%
16.6M
+10.1%
15.0M
+7.4%
14.0M
+13.3%
12.4M
Cost of Revenue
6.8M
-22.9%
8.8M
+21.6%
7.3M
-9.2%
8.0M
+10.0%
7.3M
Gross Profit
7.0M
-9.1%
7.7M
-0.6%
7.8M
+29.5%
6.0M
+18.0%
5.1M
Operating Expenses
7.5M
-4.6%
7.9M
+4.3%
7.6M
+16.6%
6.5M
-4.3%
6.8M
R&D
2.1M
-6.9%
2.3M
-13.2%
2.6M
+25.6%
2.1M
+6.1%
2.0M
SG&A
5.4M
-3.7%
5.6M
+13.5%
5.0M
+12.4%
4.4M
-8.5%
4.8M
Operating Income
-521000
-178.6%
-187000
-201.1%
185.0K
+136.5%
-507000
+70.4%
-1714000
EBITDA
-200000
-229.9%
154.0K
-71.6%
542.0K
+463.8%
-149000
+88.7%
-1320000
Net Income
-667000
-139.1%
-279000
-217.7%
237.0K
+150.9%
-466000
+74.6%
-1835000
EPS (Basic)
$-0.05
-150.0%
$-0.02
-200.0%
$0.02
+166.7%
$-0.03
+76.9%
$-0.13
EPS (Diluted)
$-0.05
-150.0%
$-0.02
-200.0%
$0.02
+166.7%
$-0.03
+76.9%
$-0.13
Shares (Diluted)
13.2M
-5.0%
13.9M
-3.9%
14.5M
+4.9%
13.8M
-5.8%
14.6M
Champions Oncology (CSBR) โ€” Financials